- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02182414
Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers
July 17, 2014 updated by: Boehringer Ingelheim
Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I Administered Orally as Tablet in Single Doses of 800 mg to Healthy Volunteers, and Evaluation of the Effect of Food on the Bioavailability of a Selected Prototype (an Open-label, Two-stage, Within Parts Randomised Six-way and Two-way Crossover Phase I Study)
Study to investigate the relative bioavailability of 5 new 400 mg tablet formulations (trial formulation II prototypes) of BI 207127 compared to the current 200 mg BI 207127 tablet formulation (trial formulation I) in healthy male volunteers with the aim to identify the best formulation for further drug development (formulation finding part / trial part 1) and to investigate the effect of food on the relative bioavailability of the most promising one of these trial formulation II prototypes (food-effect part / trial part 2).
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males according to a complete medical history, including a physical examination,vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- Age 18 to 50 years, inclusive
- Body mass index 18.5 to 29.9 kg/m2, inclusive
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria:
- Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- Intake of drugs with a long half-life (> 24 hours) within at least one month prior to administration of the trial drug or during the trial
- Use of any drugs (including herbal preparations, vitamins and nutrient supplements) within 14 days prior to first administration of the trial drug or during the trial
- Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Alcohol abuse (more than 40 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to first administration of the trial drug or during the trial)
- Excessive physical activities (within one week prior to first administration of the trial drug of the trial drug or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of trial site
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 MS)
- A history of additional risk factors for Torsade de Points (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- History of photosensitivity or recurrent rash
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BI 207127 NA (TF-I)
trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
|
200 mg tablet
|
Experimental: BI 207127 NA (TF-II)
trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
|
400 mg tablet
|
Experimental: BI 207127 NA delayed release
trial part 1: 800 mg BI 207127 NA TF-II, delayed release
|
400 mg tablet
|
Experimental: BI 207127 NA extended release (10% HPMC)
trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
|
400 mg tablet
|
Experimental: BI 207127 NA extended release (15% PEO)
trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
|
400 mg tablet
|
Experimental: BI 207127 NA extended release (20% HPMC)
trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
|
400 mg tablet
|
Experimental: BI 207127 (TF-II), fed
trial part 2
|
400 mg tablet
400 mg tablet
400 mg tablet
400 mg tablet
400 mg tablet
|
Experimental: BI 207127 (TF-II), fasted
trial part 2
|
400 mg tablet
400 mg tablet
400 mg tablet
400 mg tablet
400 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for BI 207127
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Cmax (maximum measured concentration of the analyte in plasma) for BI 207127
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval from t1 to t2)
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
λz (terminal rate constant in plasma)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
t1/2 (terminal half-life of the analyte in plasma)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
MRTpo (mean residence time of the analyte in the body after p.o. administration)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
The fluctuation parameter Cmax/C12 for the ER (Extended release) formulations only
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)
Time Frame: up to 24 hours after drug administration in the food-effect part
|
up to 24 hours after drug administration in the food-effect part
|
fet1-t2 (fraction of analyte eliminated in urine compared to oral dose administered from time point t1 to time point t2)
Time Frame: up to 24 hours after drug administration in the food-effect part
|
up to 24 hours after drug administration in the food-effect part
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time Frame: up to 24 hours after drug administration in the food-effect part
|
up to 24 hours after drug administration in the food-effect part
|
RCmax,Met (the ratio of Cmax of the metabolite, CD 6168 to Cmax of the parent compound, BI207127)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
RAUC0-∞,Met (the ratio of AUC0-∞ of the metabolite, CD 6168 to AUC0-∞ of the parent compound, BI207127)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
AUC0-∞ for CD 6168
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Cmax for CD 6168
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Measurement of protein binding in human plasma for BI 207127
Time Frame: up to 48 hours after drug administration in the food-effect part
|
up to 48 hours after drug administration in the food-effect part
|
Number of patients with adverse events
Time Frame: up to 9 weeks
|
up to 9 weeks
|
Assessment of tolerability on a 4-point scale
Time Frame: 48 h after each drug administration
|
48 h after each drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 2, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 18, 2014
Last Update Submitted That Met QC Criteria
July 17, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1241.9
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on BI 207127 NA (TF-I)
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHepatitis C, ChronicFrance, Germany, Switzerland
-
Boehringer IngelheimTerminated